Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P300 amplitude

International Journal of Neuropsychopharmacology

Volumn 12, Issue 6, 2009, Pages 823-832

  Oranje, Bob ^a,d   Gispen De Wied, Christine C ^b   Westenberg, Herman G M ^b   Kemner, Chantal ^b   Verbaten, Marinus N ^c   Kahn, René S ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d University Psychiatric Center Glostrup   (Denmark)

Author keywords

Haloperidol; Ketamine; P300; Processing negativity; Selective attention

Indexed keywords

DOPAMINE 2 RECEPTOR; HALOPERIDOL; KETAMINE; PLACEBO; PROTEIN P300; AMINO ACID RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; HOMOVANILLIC ACID; PROLACTIN;

ADULT; AMPLITUDE MODULATION; ARTICLE; AUDITORY STIMULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; HUMAN; HUMAN EXPERIMENT; MALE; NEGATIVE SYNDROME; NORMAL HUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELECTIVE ATTENTION; TASK PERFORMANCE; AFFECT; ATTENTION; BEHAVIOR; BLOOD; BLOOD PRESSURE; CONTINGENT NEGATIVE VARIATION; DRUG EFFECT; DRUG INTERACTION; ELECTROENCEPHALOGRAPHY; ELECTROOCULOGRAPHY; EVENT RELATED POTENTIAL; HEART RATE; METHODOLOGY; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL RATING SCALE; REACTION TIME; TIME;

ACOUSTIC STIMULATION; ADULT; AFFECT; ATTENTION; BEHAVIOR; BLOOD PRESSURE; CONTINGENT NEGATIVE VARIATION; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ELECTROENCEPHALOGRAPHY; ELECTROOCULOGRAPHY; EVENT-RELATED POTENTIALS, P300; EXCITATORY AMINO ACID ANTAGONISTS; HALOPERIDOL; HEART RATE; HOMOVANILLIC ACID; HUMANS; KETAMINE; MALE; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TESTS; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; REACTION TIME; TIME FACTORS; YOUNG ADULT;

EID: 68849129957     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145708009814     Document Type: Article

References (42)

1. Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, Breier A (1999). Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. American Journal of Psychiatry 156, 1646-1649.
2. Andreasen NC, Flaum M, Arndt S (1992). The comprehensive assessment of symptoms and history (CASH): an instrument for assessing psychopathology and diagnosis. Archives of General Psychiatry 49, 615-623.
3. Baribeau-Braun J, Picton TW, Gosselin JY (1983). Schizophrenia: a neurophysiological evaluation of abnormal information processing. Science 219, 874-876.
4. Bartlett EJ, Brodie JD, Simkowitz P, Schlosser R, Dewey SL, Lindenmayer JP, Rusinek H, Wolkin A, Cancro R, Schiffer W (1998). Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients. American Journal of Psychiatry 155, 337-343.
5. Boutros NN, Nasrallah H, Leighty R, Torello M (1997). Auditory evoked potentials, clinical vs research applications. Psychiatry Research 69, 183-195.
6. Bramon E, Rabe-Hesketh S, Sham P, Murray RM, Frangou S (2004). Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophrenia Research 70, 315-329.
7. Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, Malhotra AK, Pickar D (1998). Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29, 142-147.
8. Clark CR, Geffen GM, Geffen LB (1987). Catecholamines and attention: II. Pharmacological studies in normal humans. Neuroscience and Biobehavioral Reviews 11, 353-364.
9. Coburn KL, Shillcutt SD, Tucker KA, Estes KM, Brin FB, Merai P, Moore NC (1998). P300 delay and attenuation in schizophrenia: reversal by neuroleptic medication. Biological Psychiatry 44, 466-474.
10. Endicott J, Spitzer RL (1978). A diagnostic interview: the schedule for affective disorders and schizophrenia. Archives of General Psychiatry 35, 837-844.
11. Frodl-Bauch T, Bottlender R, Hegerl U (1999). Neurochemical substrates and neuroanatomical generators of the event-related P300. Neuropsychobiology 40, 86-94.
12. Geisslinger G, Menzel-Soglowek S, Kamp HD, Brune K (1991). Stereoselective high-performance liquid chromatographic determination of the enantiomers of ketamine and norketamine in plasma. Journal of Chromotography 568, 165-176.
13. Green MF (1997). Schizophrenia from a Neurocognitive Perspective: Probing the Impenetrable Darkness, 1st edn. Boston: Allyn and Bacon Inc. Hillyard SA, Hink RF, Schwent VL, Picton TW (1973). Electrical signs of selective attention in the human brain. Science 182, 177-180.
14. Holcomb HH, Cascella NG, Thaker GK, Medoff DR, Dannals RF, Tamminga CA (1996). Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. American Journal of Psychiatry 153, 41-49.
15. Javitt DC, Doneshka P, Grochowski S, Ritter W (1995). Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia. Archives of General Psychiatry 52, 550-558.
16. Javitt DC, Spencer KM, Thaker GK, Winterer G, Hajos M (2008). Neurophysiological biomarkers for drug development in schizophrenia. Nature Reviews Drug Discovery 7, 68-83.
17. Jonkman LM, Kemner C, Verbaten MN, Koelega HS, Camfferman G, Gaag RJvd, Buitelaar JK, Engeland Hv (1997). Event-related potentials and performance of attention-deficit hyperactivity disorder: children and normal controls in auditory and visual selective attention tasks. Biological Psychiatry 41, 595-611.
18. Kahkonen S, Ahveninen J, Jaaskelainen IP, Kaakkola S, Näätänen R, Huttunen J, Pekkonen E (2001). Effects of haloperidol on selective attention: a combined whole-head MEG and high-resolution EEG study. Neuropsycho-pharmacology 25, 498-504.
19. Kapur S, Seeman P (2002). NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Molecular Psychiatry 7, 837-844.
20. Kenemans JL, Molenaar PC, Verbaten MN, Slangen JL (1991). Removal of the ocular artifact from the EEG: A comparison of time and frequency domain methods with simulated and real data. Psychophysiology 28, 114-121.
21. Kraepelin E (1913). Psychiatrie, ein Lehrbuch für Studierende und Ä rzte, 8th edn. Leipzig: J. A. Barth. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13, 9-19.
22. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959). Study of a new schizophrenomimetic drug: Sernyl. Archives of Neurology and Psychiatry 81, 363-369.
23. Lundberg T, Lindstrom LH, Hartvig P, Eckernas SA, Ekblom B, Lundqvist H, Fasth KJ, Gullberg P, Langstrom B (1989). Striatal and frontal cortex binding of 11-C-labelled clozapine visualized by positron emission tomography (PET) in drug-free schizophrenics and healthy volunteers. Psychopharmacology 99, 8-12.
24. Luthringer R, Rinaudo G, Toussaint M, Bailey P, Muller G, Muzet A, Macher J (1999). Electroencephalographic characterization of brain dopaminergic stimulation by apomorphine in healthy volunteers. Neuropsychobiology 39, 49-56.
25. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A (1997). Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17, 141-150.
26. Michie PT, Fox AM, Ward PB, Catts SV, Mcconaghy N (1990). Event-related potential indices of selective attention and cortical lateralization in schizophrenia. Psychophysiology 27, 209-227.
27. Näätänen R (1990). The role of attention in auditory information processing as revealed by event-related potentials and other brain measures of cognitive function. Behavioral and Brain Sciences 13, 201-288.
28. Oishi M, Mochizuki Y, Hara M, Du CM, Takasu T (1996). Effects of intravenous L-dopa on P300 and regional cerebral blood flow in parkinsonism. International Journal of Neuroscience 85, 147-154.
29. Oranje B, Gispen-de Wied CC, Verbaten MN, Kahn RS (2002). Modulating sensory gating in healthy volunteers. The effects of ketamine and haloperidol. Biological Psychiatry 52, 887-895.
30. Oranje B, Gispen-de Wied CC, Verbaten MN, Kahn RS (2006). No effects of l-dopa and bromocriptine on psychophysiological parameters of human selective attention. Journal of Psychopharmacology 20, 789-798.
31. Oranje B, van Berckel BNM, Kemner C, van Ree JM, Kahn RS, Verbaten MN (2000). The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology 22, 293-302.
32. Roth WT, Cannon EH (1972). Some features of the auditory evoked response in schizophrenics. Archives of General Psychiatry 27, 466-471.
33. Seamans JK, Yang CR (2004). The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Progress in Neurobiology 74, 1-58.
34. Seeman P, Guan HC (2008). Phencyclidine and glutamate agonist LY379268 stimulate dopamine D2 High receptors: D2 basis for schizophrenia. Synapse 62, 819-828.
35. Shelley AM, Catts SV, Ward PB, Andrews S, Mitchell P, Michie P, McConaghy N (1997). The effect of decreased catecholamine transmission on ERP indices of selective attention. Neuropsychopharmacology 16, 202-210.
36. 11C-raclopride in normal human subjects. Neuropsychopharmacology 18, 18-25.
37. van Berckel BN, Oranje B, van Ree JM, Verbaten MN, Kahn RS (1998). The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. Psychopharmacology 137, 271-281.
38. 11C]raclopride PET study of a model psychosis in humans. Journal of Psychiatry Research 34, 35-43.
39. Ward PB, Catts SV, Fox AM, Michie PT, McConaghy N (1991). Auditory selective attention and event-related potentials in schizophrenia. British Journal of Psychiatry 158, 534-539.
40. Watson TD, Petrakis IL, Edgecombe J, Perrino A, Krystal JH, Mathalon DH (2008). Modulation of the cortical processing of novel and target stimuli by drugs affecting glutamate and GABA neurotransmission. International Journal of Neuropsychopharmacology. Published online: 4 September 2008. doi:10.1017/S1461145708009334.
41. Westenberg HG, Verhoeven WM (1988). CSF monoamine metabolites in patients and controls: support for a bimodal distribution in major affective disorders. Acta Psychiatrica Scandinavica 78, 541-549.
42. Wolkin A, Sanfilipo M, Duncan E, Angrist B, Wolf AP, Cooper TB, Brodie JD, Laska E, Rotrosen JP (1996). Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms. American Journal of Psychiatry 153, 346-354.